7:50 am Chair’s Opening Remarks

Navigating NASH: What do we Know Now & How Have we Got Here?

8:00 am Rapidly & Directly Targeting Fibrosis:  Progress & Promise 

8:30 am NASH Monotherapy: A Tour of the FXR Agonist Menagerie

9:00 am Setting up Sites for Success

  • Adrienne Stoudenmire Director, Project Management, Cardiovascular/Metabolic Therapeutic Group, ICON

9:30 am Speed Networking

10:15 am Morning Break

12:30 pm Lunch & Networking

4:15 pm Afternoon Break & Networking

Tackling Translation: How we’ve Progressed & How Far we Have to go

4:30 pm The End of the Beginning in NASH Therapy; Ongoing Challenges

  • Scott Friedman Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, Icahn School of Medicine at Mount Sinai

5:00 pm Siemens Enhanced Liver Fibrosis (ELF) Test – Its Rationale & an Update on its Utility

  • Andrew Beard Head of Business Development & Partnering , Siemens Healthineers

Should we Consider NASH the Liver Manifestation of Diabetes & Employ a More Systemic Approach to Targeting Disease?

5:30 pm Triple GLP-1 Agonists in the Treatment of NAFLD & NASH Disease

6:15 pm Panel Discussion: Is the Cure for NASH Better Treatment of Obesity?

  • Alka Shaunik Senior Director – Global Medical Affairs, Sanofi
  • Scott Harris Chief Medical Officer, Altimmune
  • Manu Chakravarthy Chief Medical Officer & Senior Vice President, Axcella Health
  • Jerry Colca Chief Scientific Officer, Cirius Therapeutics
  • Scott Friedman Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, Icahn School of Medicine at Mount Sinai

6:45 pm Scientific Poster Session & Networking Drinks